ResMed is an Australian company that manufactures and sells sleep apnea machines, ventilators, and related products worldwide. Founded in 1989 to commercialize an invention by Dr. Sullivan, ResMed had revenues of $4.2 billion in fiscal 2023 and employs over 10,000 people globally, including 1,500 in Australia.
One of the company’s priority markets is India, where an estimated 100 million people suffer from obstructive sleep apnea (OSA), a potentially serious sleep disorder in which breathing repeatedly stops and starts. This condition magnifies the risk of stroke, cardiovascular disease, hypertension, and diabetes over time.
Since entering India in 2009, ResMed has worked to raise awareness about OSA among consumers and healthcare professionals. The Australian Trade and Investment Commission has assisted ResMed’s expansion in India by facilitating introductions to customers, partners, and health policymakers across various states.
Innovation is a focus for ResMed, with around 8% of revenue invested in R&D annually across innovation hubs in Australia, India, Ireland, and Singapore. ResMed’s Australian R&D center is co-located with a manufacturing facility employing over 350 people to produce connected devices for diagnosing and treating sleep apnea and other chronic diseases.
During the COVID-19 pandemic, ResMed rapidly pivoted manufacturing to produce over 150,000 ventilators in the first half of 2020. In India, ResMed has over 100 employees across Delhi, Mumbai, Kolkata, and Bangalore working with healthcare distributors to service private and public providers nationwide.
ResMed has undertaken campaigns to educate the public, medical professionals, and officials about OSA and available CPAP machine therapies. These efforts have helped make ResMed a leading CPAP and non-invasive ventilator supplier in India, securing contracts across the country including for defense forces.
In 2023, ResMed launched a Global Tech Center in Bangalore focused on R&D and support for U.S. operations, with headcount projected to reach 200 in two years.
Looking ahead, ResMed sees strong growth potential in India aided by increasing health consciousness following COVID-19 and government healthcare spending. ResMed’s focus of late has been on improving access to diagnostic services such as sleep clinics where people can get tested for sleep apnea.
